関連する実験動画
Updated: Aug 13, 2026
11:33
Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes
Published on: March 12, 2013
レニン-アンジオテンシン系遺伝子ポリモルフィズムと心房細動
Chia-Ti Tsai1, Ling-Ping Lai, Jiunn-Lee Lin
1Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Circulation
|March 17, 2004
まとめ
レニン-アニオテンシン系 (RAS) の遺伝的変異は,非家族性構造性心房細動 (AF) と関連しています. この研究は,AFに関連した特定のRAS遺伝子ポリモルフィズムを特定し,潜在的な治療目標を示唆しました.
科学分野:
- 心血管遺伝学 心血管遺伝学
- 分子心臓病学 分子心臓病学
- アトリアルフィブリレーションの病原性 病原性
背景:
- 局所的な心房レニン- ангиотензин系 (RAS) は,心房動 (AF) の発症に関与しています.
- 非家族性構造的AF病原性には,RAS感受性遺伝子が含まれる可能性があります.
研究 の 目的:
- RAS遺伝子ポリモルフィズムと非家族構造的AFとの関連を調査する.
- AFの感受性に寄与する特定のRAS遺伝子変異を特定するために.
主な方法:
- 250人のAF患者と250人の対照群を対象とした遺伝的ケース・コントロール研究.
- ACE,アンジオテンシンゲン,およびアンジオテンシンII型I受容体遺伝子ポリモルフィズムの遺伝子型決定.
- マルチロカスハプロタイプ分析とシングルロカス分析が行われました.
主要な成果:
- AF症例と対照群 (P=0.0002) の間の血管新生素遺伝子ハプロタイププロファイルにおける有意な差異 (P=0.0002).
- 血管新生遺伝子のポリモルフィズムM235T,G-6A,G-217AはAFと有意に関連していました.
- 特定のゲノタイプ (例えば,M235/M235,G-6/G-6,G-217/G-217) でAFの確率比の増加が観察されました.
- 重要な遺伝子対遺伝子の相互作用が検出されました.
結論:
- RAS遺伝子ポリモルフィズムは,非家族性構造的AFと関連しています.
- この発見は,AF治療のためのRAS阻害剤 (ACE阻害剤,アンジオテンシンII抗体) へのさらなる研究を支持する.
関連する概念動画
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...